Adia Nutrition Stock Price, News & Analysis

Adia Nutrition (OTCQB: ADIA) has engaged an independent accounting firm and securities counsel to prepare and file a Form 10 with the U.S. SEC, marking a move from OTC reporting to full SEC reporting.

The company expects to submit the Form 10 by end of November 2025, notes an SEC review/recognition period of 60 days, and anticipates the filing becoming effective by late January 2026. Full reporting will require audited financials, regular disclosures, and enhanced governance and is presented as a step toward meeting Nasdaq listing requirements and attracting institutional and accredited investors.

Adia Nutrition (OTCQB: ADIA) reported preliminary Q3 results for the quarter ended September 30, 2025 showing a revenue increase of more than 100% quarter‑over‑quarter and a profit margin exceeding 20%. Growth was attributed to higher sales of umbilical cord stem cells and exosome therapies across clinical partnerships, direct‑to‑consumer channels, and national expansion. Management described the quarter as a milestone for the company and said full reviewed financial statements will be posted on OTC Markets and filed by on or before November 15, 2025.

Contact and partnership inquiries directed to CEO Larry Powalisz.

Adia Nutrition (OTCQB: ADIA) announced the sale of its Biolete coffee subsidiary to Cement Factory LLC on October 6, 2025, while retaining an 18% ownership stake in Cement Factory.

The move shifts Adia's focus to regenerative medicine: plans include tripling its specialized sales force in 2025, expanding Adia Med clinics, and funding R&D for next‑generation therapies. The company also cited a court‑ordered cancellation of over 25 million improperly issued shares to enhance shareholder value. Proceeds from the sale will support medical expansion; investor updates will follow via SEC filings and corporate announcements.

Adia Nutrition (OTCQB: ADIA) announced a major expansion of its sales operations by tripling its sales force and establishing four specialized teams. The restructuring creates dedicated teams for the East Coast, West Coast, Central U.S., and national/international markets to promote its Adialabs product line.

The company's portfolio includes AdiaVita (100M umbilical cord stem cells and 3T exosomes per dose), AdiaLink (3.5T exosomes per dose), and Glutaryl Transdermal Glutathione Spray. The expansion aims to enhance market reach and accessibility of these regenerative medicine products to healthcare facilities across the U.S. and globally.

Adia Nutrition Inc. (OTCQB: ADIA) has discovered over 20 million potentially improperly issued shares during an internal audit of its historical share structure. The company has initiated legal proceedings to cancel these shares and return them to the treasury. The questionable shares were issued prior to current management and lack proper documentation and regulatory compliance.

CEO Larry Powalisz emphasized the company's commitment to corporate governance and shareholder value. While addressing these historical issues, Adia continues to focus on its core business of advancing stem cell therapies, including treatments for Multiple Sclerosis, orthopedic conditions, chronic pain, and wound repair.

Adia Nutrition Inc. (OTCQB: ADIA) is finalizing in-network provider status with major health insurance companies including Humana, Florida Blue, Cigna, Medicare, and Medicaid. This strategic move aims to expand patient access to the company's regenerative stem cell therapies.

The company has already submitted applications to Humana and Cigna, initiated the process with Florida Blue, and is actively pursuing Medicare and Medicaid access. This development builds upon Adia's recent partnership with the PI Doctors Elite Community, which connects Adia Labs with over 4,000 personal injury physicians nationwide.

Adia Nutrition (OTCQB: ADIA) has been selected as a preferred vendor for the PI Doctors Elite Community, gaining access to a network of over 4,000 personal injury physicians across the United States. This strategic partnership positions Adia Labs to tap into the $50 billion personal injury care market.

Through this partnership, Adia Labs will provide its regenerative products, including AdiaVita and AdiaLink, to physicians treating injury-related conditions. A key advantage is that these therapies may be covered by auto insurance when prescribed, bypassing traditional health insurance requirements.

The partnership follows Adia's recent expansion into the $25 billion wound care market and complements their national television campaign promoting regenerative solutions.

Adia Nutrition Inc. (OTCQB: ADIA) has announced a strategic partnership between its clinical division, Adia Med, and Venture Medical to enter the $25 billion U.S. wound care market. The collaboration provides Adia Med with HCPCS billable products optimized for insurance reimbursement, targeting conditions like diabetic ulcers, venous ulcers, and pressure sores.

The partnership builds on Adia Med's existing approvals with UnitedHealthcare and Aetna, with active filings for TRICARE. Venture Medical will provide patient review and preliminary insurance verification services to streamline the reimbursement process. This expansion aligns with Adia Med's strategy to create a high-margin revenue stream while expanding access to advanced wound care solutions.

Adia Nutrition (OTCQB: ADIA) has launched its second national television campaign highlighting Adia Med's regenerative stem cell treatments at its Winter Park, Florida clinic. The campaign emphasizes U.S.-based therapies for conditions including sports injuries, orthopedic care, chronic pain, and wound repair.

The company is targeting the $25 billion wound care market and aims to make regenerative therapies more accessible domestically. Adia Med is currently in-network with UnitedHealthcare and Aetna, with pending TRICARE approval. The initiative is supported by favorable legislation like Florida's SB1768, which recognizes stem cell therapy benefits.